Evaluation Sub-Committee - Applications scheduled to be considered
- 1555.1 - Endoscopic sleeve gastroplasty for the treatment of patients with Class I and II obesity who have failed first line (lifestyle modification) and second line (pharmacotherapy) treatments
- 1657.1 - Rhenium-188 brachytherapy for non-melanoma skin cancer
- 1708.1 - Hepatitis Delta Virus (HDV) RNA PCR testing to determine eligibility for PBS-subsidised bulevirtide (HEPCLUDEX) for treatment of HDV
- 1754 - Surgical Procedures for Gender Affirmation in Adults with Gender Incongruence
- 1767 – Immunohistochemistry testing for Claudin 18 expression in patients with gastric or gastro-oesophageal junction cancers, to determine eligibility for PBS subsidised zolbetuximab treatment
- 1769 - Human leukocyte antigen (HLA) sensitivity to carbamazepine
- 1772 - Single chamber leadless pacing with atrio-ventricular synchronous pacing in patients with bradycardia
- 1774 - Newborn bloodspot screening for glycogen storage disease, Type II (Pompe disease)
- 1776 - Newborn bloodspot screening for mucopolysaccharidosis Type II (MPS II)
- 1779 - Testing of tumour tissue to detect FGFR2 fusions or rearrangements in people with cholangiocarcinoma, to determine eligibility for treatment with PBS subsidised futibatinib
- 1782 - Genetic testing to detect estrogen receptor 1 (ESR1) mutations in patients with estrogen receptor (ER)-positive, HER2-negative, locally advanced or metastatic breast cancer, to determine eligibility for treatment with PBS subsidised elacestrant
- 1791 - Dinutuximab beta for primary relapse and refractory high risk neuroblastoma
Consultation Input:
MSAC values consultation input from individuals and organisations with an interest in an application that it is considering, including experience of the medical conditions, services or technologies being addressed by the application.It is anticipated that the above-mentioned applications will proceed to MSAC in April 2025. Consultation input must be received by no later than Friday 14 February 2025 for it to be considered by MSAC. A link to the Consultation Survey is available on the relevant application webpage.
Further information on MSAC’s consultation process is also available on the MSAC website.